55.26
+0.07(+0.13%)
Currency In USD
| Previous Close | 55.19 |
| Open | 53.84 |
| Day High | 56.08 |
| Day Low | 52.82 |
| 52-Week High | 57.5 |
| 52-Week Low | 13.37 |
| Volume | 608,328 |
| Average Volume | 745,132 |
| Market Cap | 2B |
| PE | -15.79 |
| EPS | -3.5 |
| Moving Average 50 Days | 46.55 |
| Moving Average 200 Days | 32.92 |
| Change | 0.07 |
If you invested $1000 in Dianthus Therapeutics, Inc. (DNTH) since IPO date, it would be worth $237.86 as of March 03, 2026 at a share price of $55.26. Whereas If you bought $1000 worth of Dianthus Therapeutics, Inc. (DNTH) shares 5 years ago, it would be worth $262.04 as of March 03, 2026 at a share price of $55.26.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Dianthus Therapeutics to Participate in The TD Cowen 46th Annual Health Care Conference
GlobeNewswire Inc.
Feb 24, 2026 12:00 PM GMT
NEW YORK and WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune dise
Dianthus Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
GlobeNewswire Inc.
Feb 05, 2026 12:00 PM GMT
NEW YORK and WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune dise
Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 05, 2026 12:00 PM GMT
NEW YORK and WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune dise